Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility
By Elana Gotkine HealthDay Reporter
MONDAY, April 7, 2025 -- Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in JAMA Network Open.
Diya Surie, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined characteristics associated with RSV vaccine receipt and knowledge and attitudes relating to RSV vaccines during the first season of RSV vaccine use from Oct. 1, 2023, to April 30, 2024, among adults aged 60 years or older hospitalized with RSV-negative acute respiratory illness.
Of the 6,746 hospitalized adults aged 60 years or older, 10.4 and 89.6 percent were RSV-vaccinated and unvaccinated, respectively. The researchers found that 47.2 percent of the 3,219 unvaccinated adults who responded to RSV knowledge questions had not heard of RSV or were unsure; 78.5 percent were unsure if they were eligible for vaccination or thought they were not. Characteristics associated with RSV vaccination were age 75 years or older and being male (adjusted risk ratios [aRRs], 1.23 and 1.15, respectively), having pulmonary disease and immunocompromised status (aRRs, 1.39 and 1.30, respectively), low or moderate social vulnerability index (aRR, 1.47 for both), and educational level consisting of four or more years of college, at least some college or technical training, or grade 12 or General Education Development (aRR, 2.91, 1.85, and 1.44, respectively) in adjusted analyses. Residents of long-term care facilities, patients with Medicaid coverage, and uninsured patients were less likely to have RSV vaccination.
"Ongoing monitoring in future RSV seasons is needed to determine whether simplified recommendations, increases in awareness of RSV disease and vaccine information, and expansion in access to primary prevention services will lead to improved RSV vaccination coverage among older adults at higher risk for severe disease," the authors write.
Several authors disclosed ties to the biopharmaceutical industry; two authors disclosed holding relevant patents.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Widespread Decline Seen in MMR Vaccination Rates After COVID-19
THURSDAY, June 5, 2025 -- A widespread decrease in measles-mumps-rubella (MMR) vaccination rates was seen after the COVID-19 pandemic, according to a research letter published...
Cardiorespiratory Effects of Smoke Fine Particulate Matter From Wildfires Can Persist for Months
THURSDAY, June 5, 2025 -- The cardiorespiratory effects of smoke fine particulate matter (PM2.5), a primary wildfire emission that can spike for months after a wildfire begins...
Parents Appear Receptive to Children Receiving HPV Vaccine at 9 or 10 Years of Age
MONDAY, June 2, 2025 -- Clinicians consider administration of human papillomavirus (HPV) vaccine as feasible at age 9 to 10 years, and parents appear to be receptive to discussing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.